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Diabetes mellitus is a world health problem, 
affecting any age groups. It is defined as a state 
of chronic hyperglycemia, i.e. an excessive blood 
glucose concentration (3). Renal damage is a severe 
microvascular diabetic complication in patients with 
insulin-dependent diabetes mellitus (IDDM) leading 
to their death. Approximately 30-40% of such patients 
ABSTRACT
PURPOSE: The aim of this study was to determine the prevalence of tubular enzymes such as N-acetyl-
β-D-glucosaminidase (NAG), alanine aminopeptidase (AAP) and gamma glutamyl transferase (γ-GT), α1-
microglobulin, β2-microglobulin (β2-M) as well as microalbuminuria among patients with diabetes melli-
tus.
MATERIAL AND METHODS: Biomarkers were evaluated in 285 type 1 diabetes mellitus patients and 30 
healthy volunteers as a control group. Urinary levels of tubular enzymes such as NAG, AAP and γ-GT as well 
as microalbuminuria, α1-microglobulin and β2-M were determined by routine methods. Diabetes mellitus 
patients were divided into two groups - with normoalbuminuria (3-30 mg/L) and microalbuminuria (31-300 
mg/L).
RESULTS: Compared with healthy individuals, diabetes mellitus patients with normoalbuminuria excret-
ed significantly higher levels of urinary NAG (p<0,05). In patients with microalbuminuria, the most signif-
icant changes of urinary NAG, AAP and g-GT, serum cystatin C and β2-M (p<0,001) were established. There 
was no significant difference between the patients and controls in respect to serum/urine creatinine. Uri-
nary α1-microglobulin level was higher in the patients with poor glucose control (HbA1c >8,5%) and directly 
related to albuminuria. A significantly decrease of creatinine clearance in these patients was found out, too.
CONCLUSION: Measuring the urinary NAG excretion, α1-microglobulin and cystatin C could be useful for 
the assessment of renal failure in diabetes mellitus patients. The activity of AAP and γ-GT is a less sensi-
tive indicator of tubular lesions. The levels of β2-M and cystatin C which diagnostic accuracies are superi-
or to those of serum creatinine represent early indicators of incipient diabetic nephropathy. Therefore, uri-
nary biomarkers are useful in early detection of tubular and glomerular lesions in type 1 diabetes mellitus 
patients.
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develop end-stage renal disease (11) and require 
either dialysis, or renal transplantation for survival 
(29). Epidemiological studies demonstrate that 20-
30% of all type 1 diabetes mellitus patients with 
disease duration of 15-25 years develop a clinically 
significant renal disease. Thus, diagnosis of renal 
complication at an earlier stage would be critical 
and help reducing the morbidity and mortality 
rates. Diabetic nephropathy is the most common 
cause of end-stage renal failure in both IDDM and 
non-insulin dependent diabetes mellitus (NIDDM) 
(22). At the early stages, there are no clinical signs 
or symptoms of renal disease. The first clinical 
evidence of nephropathy is microalbuminuria (i. 
e. the appearance of low, but abnormal, albumin 
levels in the urine >30 mg/24 h). Without specific 
interventions, approximately 80% of IDDM patients 
present with increased urinary albumin excretion 
at a rate of 10-20% per year to the stage of overt 
nephropathy or macroalbuminuria (>300 mg/24 h 
or clinical albuminuria) over 10-15 years, developing 
hypertension along the way. Approximately 30% of 
type 2 diabetes mellitus individuals present with 
microalbuminuria or macroalbuminuria (overt 
nephropathy) shortly after the diagnosis of their 
illness as diabetes actually exists since many years 
onwards (22).
Serum and urinary biomarkers, both 
glomerular and tubular, in such patients play an 
important role in the early detection of renal damage 
(11). Urine as a diagnostic medium allows for non-
invasive detection of biomarkers, including some of 
them that are associated with both types of diabetes 
and its complications. Detection of renal tubular 
proteins and enzymes in the urine demonstrates a 
tubular involvement that leads to renal complications 
of diabetes mellitus (1,23). The markers of tubular 
lesions include some urinary enzymes such as 
β-N-acetyl-β-D-glucosaminidase (β-NAG), -GT 
and AAP as well as tubular low molecular weight 
(LMW) proteins - 1-microglobulin and β2-
microglobulin. Assessment of urinary enzymes 
is used in clinical diagnostic practice concerning 
the renal parenchymal tubular impairment (6,7). 
NAG is one of the most important and frequently 
evaluated urinary enzymes. It is a high-molecular 
weight hydrolytic lysosomal enzyme. Principally, it 
originates in proximal tubules and normally can’t 
pass through the glomerular filtration (12). It is a very 
sensitive and reliable marker of renal failure (22). 
Gamma glutamyl transferase ( -GT) and 
alanine aminopeptidase (AAP) in urine originate 
from the surface of brush border of epithelial cell 
membrane in the proximal tubular lumen (28). 
Increased urinary -GT and AAP concentrations 
are observed in the patients with diabetes mellitus 
without signs of renal functional disorders or even 
microalbuminuria. Urinary enzyme excretion 
relates to the duration, regulation (HbA1c level) 
and degree of renal functional damage. LMW 
proteins, 1-microglobulin and β2-microglobulin 
(β2-M), in unbound form freely filtered through 
the renal glomerular basement membrane are 
reabsorbed by the proximal tubular cells (10). Hence, 
any proximal tubular cell dysfunction results in 
increased quantities of these proteins in urine (19). 
Urinary 1-microglobulin is higher in both IDDM 
(24) and NIDDM subjects than that in normal 
control ones and is present even without any clinical 
nephropathy. In NIDDM subjects, 1-microglobulin 
excretion directly correlates with albuminuria (12) 
and HbA1c levels (18) and decrease with improved 
glycemic control (9). Cystatin C is another LMW 
protein freely filtered by the glomerulus (5,8). The 
serum concentration of cystatin C is less dependent 
on extrarenal factors than in the case of creatinine 
(13,15). Early detection of renal function impairment 
in microalbuminuric diabetes mellitus patients 
would be of great value allowing the accurate 
treatment, adjustment of drug dose, and prevention 
of more severe renal damage (17,28). Previous studies 
demonstrate the superiority of serum cystatin 
C compared to creatinine in the evaluation of 
glomerular filtration rate (GFR) (11,20,25), especially 
when there is a minor GFR reduction (24,28). 
This objective of the present study was to 
evaluate the clinical usefulness of sensitive urinary 
biomarkers such as urinary enzymes and LMW 
proteins in predicting the renal impairment in 
normoalbuminuric and microalbuminuric diabetes 
mellitus patients and the association between 
albuminuria and serum creatinine and cystatin C.
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MATERIAL AND METHODS
The study covered of 285 randomly selected 
IDDM patients. They were on human insulin from 
the time of diagnosis and presented with a normal 
serum creatinine and without any signs of clinical 
nephropathy. A total number of 30 healthy subjects 
(25 men and 15 women aged 33,0±6,5 years) were 
randomly selected as a control group without any 
inflammatory conditions, illness and abnormalities 
in carbohydrate metabolism. The Ethics Committee 
approved the study protocol and every participant 
signed a fully informed consent to take part in the 
study. Venous blood specimens were collected from 
the subjects of both groups after a fasting state into 
two test tubes (one without anticoagulants and 
another with K3EDTA as anticoagulant). A 24-
hour urine was collected from patients and controls 
for measuring the urinary creatinine, creatinine 
clearance, proteins and enzymes.
Glycemic control was assessed by measuring the 
glucose and glycohemoglobin in HbA1c used test kits 
from Roche Diagnostic. Serum/urine creatinine and 
urea were determined with standardized test applied 
in Cobas Integra analyzer. Spot urine samples were 
used to measure the excretion of the following urinary 
LMW proteins: 1-microglobulin, β2-microglobulin, 
serum cystatin C and microalbuminuria by means 
of immunoturbidimetric methods applied in DAKO 
tests. Normoalbuminuria and microalbuminuria 
were defined as below 30 mg/24 h and 31-300 mg/24 
h, respectively. Urinary enzyme activity of NAG, 
AAP, and -GT was determined with the methods 
of Jung (18). The activity was expressed in U/mmol 
creatinine. Creatinine clearance (CCr mL/min) was 
calculated with reference to age, sex, serum and 
urine creatinine concentrations using the standard 
Cockrofts formula. 
A nonparametric statistical analysis was used. 
Any data were presented as mean±standard error 
of the mean (SEM) and analyzed using an IBM 
personal computer. The differences between the two 
groups were calculated with Student’s unpaired t-
test. Values of p <0,05 were considered statistically 
significant. Linear correlations between different 
variables (urinary enzymes and proteins) were 
estimated.
RESULTS
Table 1 shows the demographic data of 





gender (males/females) 20/10 96/74 65/50
age (years) 33±6,5 50,0±3,2 57,3±4,9
fasting glucose (mmol/L) 4,8±1,4 6,7±1,3* 10,7±1,5**
serum creatinine mol/L 86,0±12,0 89,0±9,0 94,0±10,2
urinary creatinine (mmol/L) 12,6±5,3 11,3±6,0 13,9±3,5
creatinine clearance (mL/min) 90,2±4,6 82,5±5,9 67,3±8,0**
cystain C (mg/L) 0,9±0,40 0,98±0,5 1,38±0,12*
HbA1c (%) 4,2±0,15 7,1±0,6** 8,9±0,75**
microalbuminuria (mg/L) 12,3±3,9 24,6±3,9* 82,5±20,6**
disease duration (years) - 12,6±4,2 15.3±2,9
Data are presented as mean±SEM; *p<0,01; **p<0,001
Table 1. Biochemical and clinical characteristics of the patients and controls
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no significant differences between the patients 
and controls. In the control group, no significant 
differences are observed in the values of urinary 
enzymes and LMW proteins between males and 
females (p>0,05). There is a statistically significant 
increase of fasting blood glucose and HbA1c in 
diabetes mellitus patients. There are no statistically 
significant changes of serum and urine creatinine 
concentrations between the examined groups. There 
is a significant reduction of creatinine clearance in 
diabetes mellitus patients with microalbuminuria 
than of that in the control group (p<0,01). However, 
there are significant differences between the mean 
values of urinary microproteins in the control and 
the normoalbuminuric patients (p<0,01).
In diabetes mellitus patients with 
normoabuminuria and good metabolic control 
(HbA1c <8,0%), there is a statistically significant 
increase of urinary NAG and 1-microglobulin 
(p<0,05) (Table 2). 
AAP, -GT and β2-M show no statistically 
reliable changes among the patients compared 
with those of the control group. However, in the 
patients with microalbuminuria and poor metabolic 
control (HbA1c >8,0%) our results demonstrate 
a significantly higher excretion of NAG and 1-
microglobulin (p<0,001) than of the AAP, -GT and 
β2-M (p<0,01).
The correlation coefficient between the different 
urinary biomarkers is displayed on Table 3. There is a 
significant positive correlation in normoalbuminuric 
diabetes mellitus patients between the urinary 
enzymes and albuminuria (p<0,01). LMW protein, 







NAG (U/mmol creatinine) 0,75±0,5 2,05±0,9* 6,8±0,7**
AAP (U/mmol creatinine) 1,1±0,3 1,7±0,6 2,4±0,8*
-GT (U/mmol creatinine) 1,42±0,4 1,55±0,7 2,75±0,95*
1-microglobulin  (mg/L) 8,0±4,0 11,6±2,1* 16,8±4,3**
β2-M (mg/L)                      0,105±0,7 0,111±0,5 0,269±0,15*
Data are presented as mean±SEM; *p<0,01; **p<0,001
Тable 2. Urinary biomarkers of the patients and controls
Biomarker Normoalbuminuric Microalbuminuric






















urinary β2-M albuminuria n. c. 0,412*
n. c.= no correlation; *p<0,01; **p<0,001 
Table 3. Correlation between urinary enzymes, LMW proteins and albuminuria
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too, however, β2-M correlation coefficient is small. 
Urinary microproteins don’t possess any positive 
correlation with the enzyme activities between the 
controls and the patients with normoalbuminuria 
However, in cases with microalbuminuria, there 
is a very strong positive correlation between 
urinary enzymes such as NAG, AAP and -GT and 
microalbumins (p<0,001). The concentration of 1-
microglobulin during the development of albuminuria 
shows a very strong positive correlation (r=0,708; 
p<0,001). On the other hand, β2-M concentration 
possesses a smaller correlation coefficient.
There is no positive correlation between 
urinary enzymes and microproteins in diabetes 
mellitus patients with normoalbuminuria. Brush 
border enzymes such as AAP and -GT show a good 
correlation with NAG (p<0,01) in such patients.
A group of patients is separated at a late stage of 
development of diabetic nephropathy, where besides 
pathoanatomical and morphological alteartions of 
glomerular basal membrane, there are significant 
changes of the activity of examined tubular enzymes, 
too. It should be noted that the urinary 2-M 
concentration is significantly altered, which suggests 
changes in the structure of the glomerular basal 
membrane (Table 4).
DISCUSSION
There is no reliable therapy of diabetes mellitus 
complications in most patients, therefore preventing 
or delaying these complications contributes to 
reducing the morbidity and mortality rates (3). Several 
known risk factors such as age, age of disease onset, 
abnormal metabolic environment, hyperglycemia, 
arterial hypertension, protein overload, disease 
duration, and tobacco smoking are important in 
diabetic complications (3). Arterial hypertension 
and poor glycaemic control are causal risk factors 
for microalbuminuria. Recent data suggest that the 
kidney function in IDDM does not depend only on the 
duration of the disease, but also on other factors such 
as presence of microalbuminuria and proteinuria. 
We do not reveal any significant differences between 
diabetes mellitus patients and controls concerning 
age and sex. Mean disease duration is longer in 
microalbuminuric patients (15,3±2,9 years). This 
finding is similar to other results (23) and indicates a 
higher risk of microlabuminuria in the patients with 
longer disease duration. 
Urinary microprotein excretion is elevated in 
the patients with a poor metabolic control (HbA1c 
>8,0%) compared to those with a good one (p<0,001). 
There are no significant differences of the serum 
and urine creatinine levels and creatinine clearance 
between the control group and normoalbuminuric 
diabetes mellitus patients. We prove that these 
urinary enzymes and LMW proteins are very sensitive 
parameters for early diagnosis of tubular cell lesions. 
Urinary NAG excretion is statistically significantly 
higher in the patients with microalbuminuria than 
           Controls Patients with diabetic nephropathy
UNAG (U/mmol creatinine) 0,75±0,5 8,3±0,9**
UAAP (U/mmol creatinine) 1,1±0,3 3,6±0,9*
U -GT (U/mmol creatinine) 1,42±0,4 4,8±1,05**
U 1-microglobulin (mg/L) 8,0±4,0 29,3±5,6**
Uβ2-M (mg/L) 0,105±0,7 1,35±0,25**
serum creatinine ( mol/L) 86,0±12,0 118,0±15,5*
cystatin C (mg/L) 0,9±0,40 1,95±0,23**
Data are presented as mean±SEM; *p<0,01; **p<0,001
Table 4. Biomarkers in patients during the stages of diabetic nephropathy
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in the controls (p<0,001) and there exists a positive 
correlation with AAP and -GT. The quantitative 
analysis of AAP and -GT demonstrates that they 
are less sensitive biomarkers (p<0,01) of renal tubular 
damage than NAG. Our data confirm other results 
(27) that excretion of urinary tubular enzymes is 
influenced by the some pathological conditions 
such as diabetes mellitus. Urinary excretions of 
renal tubular enzymes and LMW proteins are 
recommended as useful markers for detection of 
minor changes in proximal tubular function long 
before elevation of other markers such as proteinuria 
and serum creatinine increase (14). 
Our data are similar to other findings that 
urinary NAG excretion is significantly higher in 
IDDM patients than in control subjects (p<0,001) 
and is significantly associated with disease duration 
(4,11,27). Urinary 1-microglobulin concentration 
and albumin directly relate to duration, severity 
and control of diabetes mellitus. Our results 
confirm other reports (21) about patients with 
IDDM duration longer than 10 years. In addition 
to albuminuria measuring glomerular dysfunction, 
urinary α1-microglobulin estimating proximal 
tubular dysfunction is useful for the early detection of 
nephropathy in diabetes mellitus. The higher urinary 
β2-M excretion in microalbuminuria (p<0,01) 
indicates an increased glomerular permeability and/
or decreased reabsorption of proximal tubules. This 
is a sensitive biomarker of increased glomerular 
filtration and proximal renal tubular function and 
thus an early indicator of diabetic nephropathy (2). 
Elevated cystatin C concentration as an early marker 
of GFR changes among the diabetes mellitus patients 
with microalbuminuria >300 mg/24 h is due to poor 
metabolic control, hypertensive status and disease 
duration. There is a direct link between proteinuria 
and tubulointerstitial injury in the progression of 
glomerular disease (16,26).
CONCLUSION
Our results suggest that urinary NAG and 
1-microglobulin excretion and cystatin C are 
the most sensitive parameters for early diagnosis 
of tubular cell damages. NAG activity increases 
before microalbuminuria appearance and its values 
are highest in such diabetes mellitus patients. 
The activities of AAP and -GT are less sensitive 
biomarkers of tubular damage than that of β-NAG. 
Urinary β2-M and serum cystatin C levels are sensitive 
markers for increased GFR and early indicators for 
advanced diabetic nephropathy. Site-specific urinary 
biochemical markers provide valuable information 
about early renal proximal tubular lesion that 
ultimately may precede glomerular permeability 
disorders in diabetes mellitus.
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